AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18350566 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg eszopiclone
Number of subjects: 64
Study 18350566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 15699766 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 108
Study 15699766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 12006422 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose inhaled fluticasone propionate (FP), 2,000 microg/d for 8 weeks
Number of subjects: 9
Study 10589605 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg IV
Number of subjects: 54
Study 9082800 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbipolar dissection (MBPD)
Number of subjects: 200
Study 9082800 — intervention group
Group type: COMPARATOR
Intervention: Cold knife dissection with suction cautery (CKC)
Number of subjects: 200
Study 1745846 — intervention group
Group type: EXPERIMENTAL
Intervention: OM-85 BV
Number of subjects: 116
Study 1745846 — intervention group
Group type: EXPERIMENTAL
Intervention: OM-85 BV (subgroup aged 6 years and less)
Number of subjects: 116
Study 1745846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 6354932 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg three times daily)
Number of subjects: 9
Study 6354932 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg three times daily)
Number of subjects: 9
Study 6354932 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril plus Nifedipine
Number of subjects: 9
Study 6354932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30690554 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan
Number of subjects: 3
Study 30690554 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin
Number of subjects: 3
Study 29128183 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative neuromonitoring
Number of subjects: 1328
Study 29128183 — intervention group
Group type: COMPARATOR
Intervention: Non-intraoperative neuromonitoring
Number of subjects: 1328
Study 27812649 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbiotic product (Lactobacillus bulgaricus, Lactobacillus rhamnosus, and fructo‐oligosaccharides) administered twice a day for seven days via oral/enteral route
Number of subjects: 116
Study 27812649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 27812649 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbiotic product
Number of subjects: 116
Study 27812649 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbiotic product and Placebo
Number of subjects: 116
Study 24557492 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol treatment (group 2)
Number of subjects: 58
Study 24557492 — intervention group
Group type: COMPARATOR
Intervention: Prepropranolol treatment (group 1)
Number of subjects: 58
Study 24557492 — intervention group
Group type: COMPARATOR
Intervention: Nonpropranolol treatment (group 3)
Number of subjects: 58
Study 22784344 — intervention group
Group type: EXPERIMENTAL
Intervention: TJ-15 plus TJ-17
Number of subjects: 24
Study 22784344 — intervention group
Group type: COMPARATOR
Intervention: TJ-15
Number of subjects: 24
Study 20830534 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acids starting within 24 h of birth, advanced to 2.5 g/kg per day by day 3
Number of subjects: 17
Study 20830534 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 17
Study 18190318 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7
Number of subjects: 64
Study 18190318 — intervention group
Group type: COMPARATOR
Intervention: PPV23
Number of subjects: 64
Study 15220202 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose at baseline
Number of subjects: 837
Study 15220202 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance
Number of subjects: 837
Study 15220202 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight individuals
Number of subjects: 837
Study 15220202 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese individuals
Number of subjects: 837
Study 15220202 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyslipidemia or hypertension
Number of subjects: 837
Study 15220202 — intervention group
Group type: EXPERIMENTAL
Intervention: Low insulin sensitivity and low insulin response
Number of subjects: 837
Study 15220202 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA-IR and Sluiter's Index
Number of subjects: 837
Study 15220202 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline impaired fasting glucose, BMI, HOMA-IR, and Sluiter's Index
Number of subjects: 837
Study 15220202 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-standardized incidence rate
Number of subjects: 837
Study 12469360 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA) treatment
Number of subjects: 285
Study 12469360 — intervention group
Group type: COMPARATOR
Intervention: Insulin treatment (Control)
Number of subjects: 285
Study 10099053 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ebastine (elderly)
Number of subjects: 37
Study 10099053 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ebastine (young)
Number of subjects: 37
Study 10099053 — intervention group
Group type: COMPARATOR
Intervention: 10 mg ebastine (both groups)
Number of subjects: 37
Study 10099053 — intervention group
Group type: COMPARATOR
Intervention: Electrocardiography (both groups)
Number of subjects: 37
Study 7806020 — intervention group
Group type: EXPERIMENTAL
Intervention: IDDM women with microalbuminuria
Number of subjects: 42
Study 7806020 — intervention group
Group type: COMPARATOR
Intervention: IDDM women with normoalbuminuria
Number of subjects: 42
Study 2594822 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline via Turbuhaler
Number of subjects: 8
Study 2594822 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol via Rotahaler
Number of subjects: 8
Study 2594822 — intervention group
Group type: EXPERIMENTAL
Intervention: Both terbutaline and salbutamol at highest dose
Number of subjects: 8
Study 1100306 — intervention group
Group type: EXPERIMENTAL
Intervention: Prorenoate
Number of subjects: 12
Study 1100306 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone
Number of subjects: 12
Study 30831600 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ferritin <15 μg/L
Number of subjects: 792
Study 30831600 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum soluble transferrin receptor (sTfR) >4.4 mg/L
Number of subjects: 792
Study 30831600 — intervention group
Group type: EXPERIMENTAL
Intervention: Calculated total body iron <0 mg/kg
Number of subjects: 792
Study 29211949 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocaril® Bi‐Fluoré 250 (1500 ppm F as NaF+1000 ppm F as SMFP)
Number of subjects: 0
Study 29211949 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard toothpaste (1100 ppm as NaF/silica)
Number of subjects: 0
Study 29211949 — intervention group
Group type: EXPERIMENTAL
Intervention: LacerAnticaries (2500 ppm F as SMFP)
Number of subjects: 0
Study 29211949 — intervention group
Group type: EXPERIMENTAL
Intervention: Elmex® Caries Professional™ (1450 ppm F as SMFP+1.5% arginine)
Number of subjects: 0
Study 29211949 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate® Triple Action (1450 ppm F as SMFP)
Number of subjects: 0
Study 29211949 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 ppm F)
Number of subjects: 0
Study 27050997 — intervention group
Group type: EXPERIMENTAL
Intervention: GR‐α expression in tonsil tissues of OSAHS children
Number of subjects: 30
Study 27050997 — intervention group
Group type: EXPERIMENTAL
Intervention: GR‐β expression in tonsil tissues of OSAHS children
Number of subjects: 30
Study 24805901 — intervention group
Group type: EXPERIMENTAL
Intervention: Online mediated social support
Number of subjects: 0
Study 24805901 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective monitoring of physical activity
Number of subjects: 0
Study 24805901 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured high‐intensity workouts
Number of subjects: 0
Study 24805901 — intervention group
Group type: EXPERIMENTAL
Intervention: Point‐of‐decision prompts
Number of subjects: 0
Study 22801470 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward head posture corrective exercise programme
Number of subjects: 76
Study 22801470 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment (stretching and strengthening exercises)
Number of subjects: 76
Study 19439637 — intervention group
Group type: EXPERIMENTAL
Intervention: Marinated broiler breast fillets deboned pre-rigor with 1% salt and 0.45% phosphate
Number of subjects: 400
Study 19439637 — intervention group
Group type: COMPARATOR
Intervention: Marinated broiler breast fillets deboned postrigor with 1% salt and 0.45% phosphate
Number of subjects: 400
Study 17462541 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% alcohol beer
Number of subjects: 16
Study 17462541 — intervention group
Group type: COMPARATOR
Intervention: Usual alcohol intake
Number of subjects: 16
Study 16496609 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients (HT) with untreated essential hypertension
Number of subjects: 147
Study 16496609 — intervention group
Group type: EXPERIMENTAL
Intervention: Deletion alleles (D or 4G) in hypertensive patients
Number of subjects: 147
Study 16496609 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid disorders in hypertensive patients
Number of subjects: 147
Study 16496609 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE I/D and PAI‐1 4G/5G polymorphisms
Number of subjects: 147
Study 12205547 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (GTN) 10 mg/24 hours adhesive patch
Number of subjects: 31
Study 12205547 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 31
Study 12205547 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (GTN)
Number of subjects: 31
Study 10542357 — intervention group
Group type: EXPERIMENTAL
Intervention: Slice adaptation method for cine velocity mapping
Number of subjects: 15
Study 10542357 — intervention group
Group type: COMPARATOR
Intervention: Spatially fixed slice method
Number of subjects: 15
Study 10542357 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion correction for patients with clinical aortic regurgitation
Number of subjects: 15
Study 8547379 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive multidisciplinary geriatric assessment in an inpatient geriatric assessment unit (mean length of stay, 16.5 days)
Number of subjects: 312
Study 8547379 — intervention group
Group type: COMPARATOR
Intervention: Usual home care
Number of subjects: 312
Study 8547379 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive multidisciplinary geriatric assessment in an inpatient geriatric assessment unit
Number of subjects: 312
Study 2183868 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50‐100 mg once daily)
Number of subjects: 69
Study 2183868 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine (20‐40 mg once daily)
Number of subjects: 69
Study 2183868 — intervention group
Group type: COMPARATOR
Intervention: Combination of atenolol (50 mg) and nitrendipine (20 mg) once daily
Number of subjects: 69
Study 2183868 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 69
Study 6258620 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline given 30 min before paracetamol
Number of subjects: 35
Study 6258620 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline given immediately before paracetamol
Number of subjects: 35
Study 6258620 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral salbutamol
Number of subjects: 35
Study 6258620 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol given alone
Number of subjects: 35
Study 31012497 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 weeks of progressive vigorous‐intensity interval training performed three times per week
Number of subjects: 77
Study 31012497 — intervention group
Group type: COMPARATOR
Intervention: Control group (received tailored lifestyle recommendations)
Number of subjects: 77
Study 27916338 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm band worn for more than 6 hours daily for at least 6 months
Number of subjects: 110
Study 27916338 — intervention group
Group type: COMPARATOR
Intervention: Non-band group (control)
Number of subjects: 110
Study 27916338 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm band
Number of subjects: 110
Study 26044442 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure management (target systolic blood pressure <140 mmHg)
Number of subjects: 2839
Study 26044442 — intervention group
Group type: COMPARATOR
Intervention: Guideline-based blood pressure management (target systolic blood pressure <180 mmHg)
Number of subjects: 2839
Study 26044442 — intervention group
Group type: EXPERIMENTAL
Intervention: All grading scales (original intracerebral hemorrhage, modified intracerebral hemorrhage, intracerebral hemorrhage grading scale)
Number of subjects: 2839
Study 24229558 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video method
Number of subjects: 144
Study 24229558 — intervention group
Group type: EXPERIMENTAL
Intervention: Role-playing method
Number of subjects: 144
Study 21441882 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 305
Study 21441882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study 19797280 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention, self-monitoring of blood glucose, and insulin therapy if necessary
Number of subjects: 958
Study 19797280 — intervention group
Group type: COMPARATOR
Intervention: Usual prenatal care (control group)
Number of subjects: 958
Study 16672093 — intervention group
Group type: COMPARATOR
Intervention: No remifentanil infusion (n = 21)
Number of subjects: 67
Study 16672093 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ng mL(‐1) remifentanil (n = 24)
Number of subjects: 67
Study 16672093 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ng mL(‐1) remifentanil (n = 22)
Number of subjects: 67
Study 15596872 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 114
Study 15596872 — intervention group
Group type: COMPARATOR
Intervention: Distal protection
Number of subjects: 114
Study 10635266 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual interdental cleaning
Number of subjects: 35
Study 10635266 — intervention group
Group type: COMPARATOR
Intervention: Interclean Interdental Plaque Remover
Number of subjects: 35
Study 7502115 — intervention group
Group type: EXPERIMENTAL
Intervention: MiniMed implantable insulin pump (MIP)
Number of subjects: 36
Study 7502115 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 36
Study 2309999 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine (0.3 mg kg‐1)
Number of subjects: 170
Study 2309999 — intervention group
Group type: COMPARATOR
Intervention: Meperidine (1 mg kg‐1)
Number of subjects: 170
Study 7011964 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol + Hydrochlorothiazide (P+H)
Number of subjects: 260
Study 7011964 — intervention group
Group type: COMPARATOR
Intervention: Oxprenolol + Hydrochlorothiazide (O+H)
Number of subjects: 260
Study 30507561 — intervention group
Group type: EXPERIMENTAL
Intervention: Squatting exercise in addition to a traditional physical therapy program
Number of subjects: 30
Study 30507561 — intervention group
Group type: EXPERIMENTAL
Intervention: Squatting with hip adduction exercise in addition to a traditional physical therapy program
Number of subjects: 30
Study 28729003 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity Promotion System (APs) with a wearable device and web-based feedback system
Number of subjects: 53
Study 28729003 — intervention group
Group type: COMPARATOR
Intervention: Usual care with traditional health education
Number of subjects: 53
Study 23688197 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation (PNF)
Number of subjects: 18
Study 23688197 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive Stretching (PASS)
Number of subjects: 18
Study 22955576 — intervention group
Group type: EXPERIMENTAL
Intervention: Class II elastics (A)
Number of subjects: 32
Study 22955576 — intervention group
Group type: EXPERIMENTAL
Intervention: Class III elastics (B)
Number of subjects: 32
Study 20127794 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) for nightmares
Number of subjects: 40
Study 20127794 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 18315451 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC) 500 to 1500 mg b.i.d.
Number of subjects: 112
Study 18315451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 16222404 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral parenteral nutrition for a mean duration of 15.8 days (range 8-23)
Number of subjects: 0
Study 16222404 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 0
Study 12177649 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus cilostazol therapy (200 mg/day)
Number of subjects: 130
Study 12177649 — intervention group
Group type: COMPARATOR
Intervention: Aspirin plus ticlopidine hydrochloride therapy (200 mg/day)
Number of subjects: 130
Study 10414568 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30
Study 10414568 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 30
Study 7589028 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG) infusion at doses of 0.015, 0.25, 1.0, and 2.0 micrograms.kg‐1.min‐1
Number of subjects: 12
Study 7589028 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline) infusion
Number of subjects: 12
Study 2250227 — intervention group
Group type: EXPERIMENTAL
Intervention: LongoVital (LV)
Number of subjects: 29
Study 2250227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 7282730 — intervention group
Group type: EXPERIMENTAL
Intervention: Erosive disease identified in patients with sickle cell anemia
Number of subjects: 100
Study 7282730 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of definition of the cortical margin in the superior aspect of the calcaneus
Number of subjects: 100
Study 30905851 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency transvaginal cervico‐isthmic cerclage
Number of subjects: 3
Study 28202004 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2603618/gemcitabine
Number of subjects: 99
Study 28202004 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine
Number of subjects: 99
Study 26486789 — intervention group
Group type: EXPERIMENTAL
Intervention: FCR (fludarabine, cyclophosphamide, and rituximab)
Number of subjects: 817
Study 26486789 — intervention group
Group type: COMPARATOR
Intervention: FC (fludarabine and cyclophosphamide)
Number of subjects: 817
Study 26486789 — intervention group
Group type: EXPERIMENTAL
Intervention: FCR
Number of subjects: 817
Study 26486789 — intervention group
Group type: COMPARATOR
Intervention: FC
Number of subjects: 817
Study 24552318 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus radiotherapy and temozolomide
Number of subjects: 921
Study 24552318 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus radiotherapy and temozolomide
Number of subjects: 921
Study 21909634 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg modafinil
Number of subjects: 40
Study 21909634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 19251770 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderated support group (password-protected access to health portal)
Number of subjects: 108
Study 19251770 — intervention group
Group type: COMPARATOR
Intervention: Unmoderated support group (no password-protected access to health portal)
Number of subjects: 108
Study 17309966 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure
Number of subjects: 200
Study 17309966 — intervention group
Group type: COMPARATOR
Intervention: Clamp-and-tie technique
Number of subjects: 200
Study 16763491 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 140
Study 16763491 — intervention group
Group type: COMPARATOR
Intervention: Control group (HIV informational program)
Number of subjects: 140
Study 15252191 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 30
Study 15252191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10758467 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral etilefrine 15 mg (30 drops), 60 min before the subarachnoid block
Number of subjects: 40
Study 10758467 — intervention group
Group type: COMPARATOR
Intervention: No etilefrine (control group)
Number of subjects: 40
Study 8649652 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemia (euglycaemic hyperinsulinaemic clamp technique)
Number of subjects: 14
Study 8649652 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemia (euglycaemic hyperinsulinaemic clamp technique) + Angiotensin II (0.1 ng/kg per min)
Number of subjects: 14
Study 8649652 — intervention group
Group type: COMPARATOR
Intervention: Hyperinsulinaemia (euglycaemic hyperinsulinaemic clamp technique) in lean control group
Number of subjects: 14
Study 8649652 — intervention group
Group type: COMPARATOR
Intervention: Hyperinsulinaemia (euglycaemic hyperinsulinaemic clamp technique) in weight-matched control group
Number of subjects: 14
Study 8649652 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II
Number of subjects: 14
Study 1635123 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 adjuvant cycles of methotrexate, vinblastine and cisplatin plus doxorubicin (M‐VAC) or epirubicin (M‐VEC)
Number of subjects: 49
Study 1635123 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 49
Study 6731015 — intervention group
Group type: EXPERIMENTAL
Intervention: E-Z-CAT (barium sulphate suspension)
Number of subjects: 100
Study 6731015 — intervention group
Group type: COMPARATOR
Intervention: Gastrografin (water-soluble iodinated contrast medium)
Number of subjects: 100
Study 30761846 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic totally extraperitoneal herniorrhaphy (TEP)
Number of subjects: 302